UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000048523
Receipt number R000055287
Scientific Title Effect of tofogliflozin on glycemic fluctuation in patients with type 2 diabetes with non-alcoholic fatty liver disease (NAFLD)
Date of disclosure of the study information 2022/08/04
Last modified on 2022/07/30 10:05:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of tofogliflozin on glycemic fluctuation in patients with type 2 diabetes with non-alcoholic fatty liver disease (NAFLD)

Acronym

Effect of tofogliflozin on glycemic fluctuation in patients with type 2 diabetes with non-alcoholic fatty liver disease (NAFLD)

Scientific Title

Effect of tofogliflozin on glycemic fluctuation in patients with type 2 diabetes with non-alcoholic fatty liver disease (NAFLD)

Scientific Title:Acronym

Effect of tofogliflozin on glycemic fluctuation in patients with type 2 diabetes with non-alcoholic fatty liver disease (NAFLD)

Region

Japan


Condition

Condition

type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect of SGLT2 inhibitor (tofogliflozin) on glycemic fluctuation in patients with type 2 diabetes with NAFLD.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change in area under the curve of incremental blood glucose 2 hours after each meal before and after administration of tofogliflozin

Key secondary outcomes

The following degrees of change
Glycoalbumin
Blood glucose level 180 mg / dl or higher, 70-180 mg / dl, time ratio less than 70 mg / dl, blood glucose level less than 54 mg / dl time ratio, nighttime hypoglycemic region time ratio, average blood glucose level, blood glucose standard Deviation, blood glucose fluctuation coefficient, MODD, M value, MAGE, body weight, urinary glucose excretion
Examine the relationship between the above evaluation indicators and the FLI value at baseline (FLI value 30-60, 2 groups of 60 or more, etc.)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Tofogliflozin 20 mg once in the morning for 10 days

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Patient with Type 2 diabetes with HbA1c level of 7.0 or more and less than 11.0 who were required to be hospitalized for glycemic control
2.Patients with Fatty Liver Index of 30 or higher
3.Patients who drink less than 30g / day for men and 20g / day for women in terms of ethanol

Key exclusion criteria

1.Patients with hypersensitivity to tofogliflozin
2.Patients with contraindications to tofogliflozin
3.Patients with severe renal dysfunction eGFR oh less than 30 or end stage renal disease during dialysis
4.Patients with autoimmune hepatitis, viral liver disease, drug induced fatty liver, primary biliary cirrhosis, and metabolic liver disease
5.Patients who have been treated with SGLT2 inhibitor, GLP1 receptor agonist, and thiazolidine within 3 months before enrollment
6.Patients who the doctor deems inappropriate for participation in this study

Target sample size

24


Research contact person

Name of lead principal investigator

1st name Kumeda
Middle name
Last name Yasuro

Organization

Minami Osaka Hospital

Division name

Internal medicine

Zip code

5590012

Address

1-18-18, Higashikagaya, Suminoe-ku, Osaka, 559-0012, Japan

TEL

0666850221

Email

y_kumeda@yahoo.co.jp


Public contact

Name of contact person

1st name Kawaguchi
Middle name
Last name Yuji

Organization

Minami Osaka Hospital

Division name

Internal medicine

Zip code

5590012

Address

1-18-18, Higashikagaya, Suminoe-ku, Osaka, 559-0012, Japan

TEL

0666850221

Homepage URL


Email

y.kawaguchi@minamiosaka.com


Sponsor or person

Institute

Minami Osaka Hospital

Institute

Department

Personal name



Funding Source

Organization

Minami Osaka Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Minami Osaka Hospital

Address

1-18-18, Higashikagaya, Suminoe-ku, Osaka, 559-0012, Japan

Tel

0666850221

Email

y.kawaguchi@minamiosaka.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 08 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 07 Month 30 Day

Date of IRB


Anticipated trial start date

2022 Year 08 Month 04 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 07 Month 30 Day

Last modified on

2022 Year 07 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055287


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name